Skip to main content
DYN
NASDAQ Life Sciences

Dyne Q3 Loss Widens to $193.6M; Cash of $1.13B Funds Runway Into Q2 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$18.63
Mkt Cap
$3.462B
52W Low
$14
52W High
$27.305
52W Position info
33% above low
Off High info
32% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

DYN sits 33% above its 52-week low of $14.

Summary

Dyne reported a wider Q3 2026 net loss of $193.6 million on sharply higher R&D, while $1.134 billion in cash and securities funds operations into the second quarter of 2028 — past the January 2027 z-rostudirsen PDUFA date.


Key Events · Earnings and Guidance · DYN

  • Q3 Loss Widens on R&D Build

    Net loss was $193.6 million for Q3 2026 versus $108.0 million a year earlier, and the nine-month net loss reached $493.0 million versus $334.3 million. R&D rose to $161.7 million from $97.2 million, driven by z-rostudirsen manufacturing and FORZETTO trial activity.

  • Cash Runway Into Q2 2028

    Cash, cash equivalents and marketable securities totaled $1.134 billion at September 30, 2026, which management says funds operating expenses, debt service and capex into the second quarter of 2028.

  • July Offering and Hercules Tranche

    A July 2026 follow-on sold 21,045,000 shares for net proceeds of about $404.9 million, and the third $50.0 million Hercules tranche was drawn in June 2026, lifting principal debt to $200.0 million.

  • Debt Covenants Start July 2027

    The Hercules loan carries a minimum cash covenant of 40% of outstanding principal beginning July 1, 2027, waived while market capitalization exceeds $1.65 billion, plus a revenue covenant once FDA approval occurs.


Analysis · DYN · Life Sciences

The balance sheet is the real story here: $1.134 billion in cash and securities, topped up by a $404.9 million July offering and a $50 million Hercules tranche, funds operations into the second quarter of 2028. That runway covers the January 21, 2027 PDUFA date for z-rostudirsen and the first-quarter 2027 ACHIEVE registrational cohort readout for z-basivarsen, so the company does not need to raise equity into either binary event. The trade-off is a heavier cost base — R&D nearly doubled year over year as Dyne scales manufacturing and clinical work for z-rostudirsen and z-basivarsen — and $200 million of debt with covenants that begin testing in July 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYN was trading at $18.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $14.00 to $27.31. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $15.50 info
Change: -$10.65 (-41%) info
Market Cap: $2.904B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $15.50 info
Change: -$10.44 (-40%) info
Market Cap: $2.904B info
DYN
Jul 29, 2026, 4:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $24.81
Real-time Price: $15.50 info
Change: -$9.31 (-38%) info
Market Cap: $2.904B info